Work

Vitiligo-Like Secundary to Ribociclib: A Case Report

Year: 2025

Type: article

Abstract: Ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is widely used in the treatment of metastatic breast cancer. However, its dermatologic adverse effects, particularly vitiligo-like lesions, have been recently reported. The pathomechanisms underlying these lesions remain unclear, but immune-mediated melanocyte destruction has been proposed. A literature review reveals an increasing number of similar cases, highlighting the need for further investigation into these adverse effects’ incidence, mechanisms, and clinical implications. We present a case of vitiligo-like depigmentation in a patient undergoing ribociclib therapy.

Source: International Journal of Medical Science and Clinical Research Studies

DOI: 10.47191/ijmscrs/v5-i02-35

Authors: Carol Estefania Marquez Maldonado, Alan Larios Rojas, Lucia Achell Nava, Dolores Maribel Arellano Vivero, Guadalupe Maldonado Colin, María Azalea Loredo Alanis, Samuel Bencomo Loepky

Institutions: Institute for Social Security and Services for State Workers, Universidad Nacional Autónoma de México

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4408219207

FWCI:

Cites:

Cited by:

Related to: 10